Exelixis (EXEL) Other Non-Current Liabilities (2010 - 2026)
Exelixis (EXEL) posted quarterly Other Non-Current Liabilities of $117.3 million for Q2 2026, down 2.22% year-over-year from $120.0 million in Q2 2025, and up 12.36% quarter-over-quarter from $104.4 million in Q1 2026.
Exelixis (EXEL) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Exelixis' Other Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $117.3 million for Q2 2026.
- In Q2 2026, Other Non-Current Liabilities fell 2.22% year-over-year to $117.3 million; the TTM figure through Apr 2026 stood at $117.3 million (down 2.22% YoY), while the FY2026 annual figure was $104.4 million, down 4.11% from the prior year.
- Other Non-Current Liabilities for Q2 2026 stood at $117.3 million, up from $104.4 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $128.6 million in Q3 2025, with the low at $1.9 million in Q3 2022.
- The 5-year median for Other Non-Current Liabilities is $96.1 million (2024), against an average of $82.1 million.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities slumped 53.35% in 2022, then surged 3129.35% in 2023.
- Exelixis' Other Non-Current Liabilities stood at $68.5 million in 2022, then jumped by 37.49% to $94.2 million in 2023, then increased by 1.95% to $96.1 million in 2024, then advanced by 17.22% to $112.6 million in 2025, then advanced by 4.19% to $117.3 million in 2026.
- Business Quant data shows EXEL's Other Non-Current Liabilities at $117.3 million in Q2 2026, $104.4 million in Q1 2026, and $112.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 3, 2026 | 122.62 Mn |
| Apr 3, 2026 | 117.33 Mn |
| Jan 2, 2026 | 104.42 Mn |
| Oct 3, 2025 | 112.61 Mn |
| Jul 4, 2025 | 128.59 Mn |
| Apr 4, 2025 | 120.00 Mn |
| Jan 3, 2025 | 108.90 Mn |
| Sep 27, 2024 | 96.07 Mn |
| Jun 28, 2024 | 109.67 Mn |
| Mar 29, 2024 | 101.27 Mn |
| Dec 29, 2023 | 94.22 Mn |
| Sep 29, 2023 | 61.62 Mn |
| Jun 30, 2023 | 73.50 Mn |
| Mar 31, 2023 | 67.38 Mn |
| Dec 30, 2022 | 68.53 Mn |
| Sep 30, 2022 | 1.91 Mn |
| Jul 1, 2022 | 17.40 Mn |
| Apr 1, 2022 | 12.52 Mn |
| Dec 31, 2021 | 8.02 Mn |
| Oct 1, 2021 | 4.09 Mn |